Fluticasone nasal spray and the combination of loratadine and montelukast in seasonal allergic rhinitis

Archives of Otolaryngology - Head and Neck Surgery

Volumn 129, Issue 5, 2003, Pages 557-562

  Saengpanich, Supinda ^b   DeTineo, Marcy ^b   Naclerio, Robert M ^b   Baroody, Fuad M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; FLUTICASONE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; MONTELUKAST;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRICK TEST; QUALITY OF LIFE; QUESTIONNAIRE; RAGWEED POLLEN; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

ACETATES; ADULT; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LEUKOTRIENE ANTAGONISTS; LORATADINE; MALE; MIDDLE AGED; QUINOLINES; RHINITIS, ALLERGIC, SEASONAL;

EID: 0037954219     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.129.5.557     Document Type: Article

References (23)

1. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000;105:917-922.
2. Lis K, Malmstrom K, Nayak AS, Philip G, Malice MP, Reiss TF, for the Montelukast Fall Rhinitis Investigator Group. Treatment of fall allergic rhinitis with montelukast alone or in combination with loratadine in a multicenter, doubleblind, randomized, placebo-controlled study [abstract]. J Allergy Clin Immunol. 2001;107:S158.
3. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77-83.
4. Naclerio RM, Meier HL, Kagey-Sobotka A, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis. 1983;128:597-602.
5. Jen A, Baroody F, deTineo M, Haney L, Blair C, Naclerio RM. PRN use of Flonase reduces symptoms of ragweed rhinitis. J Allergy Clin Immunol. 2000;105:732-738.
6. Naclerio RM. Clinical manifestations of release of histamine and other inflammatory mediators. J Allergy Clin Immunol. 1999;103(suppl 3):S382-S384.
7. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy. 1986; 16:289-297.
8. Spector S. Ideal pharmacotherapy for allergic rhinitis. J Allergy Clin Immunol. 1999;103(suppl 3):S386-S387.
9. Bavel JV, Findlay SR, Hampel FC, Martin BG, Ratner P, Field E. Intranasal fluticasone propionate is more effective than terfenadine tablets for seasonal allergic rhinitis. Arch Intern Med. 1994;154:2699-2704.
10. Jordana G, Dolovich J, Briscoe MP, et al. Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 1996;97:588-595.
11. Gehanno P, Desfougeres JL. Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis. Allergy. 1997; 52:445-450.
12. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systemic review of randomized controlled trials. BMJ. 1998;317:1624-1629.
13. Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease." Ann Allergy Asthma Immunol. 2000;84:176-185.
14. Naclerio RM, Baroody FM, Togias AG. The role of leukotrienes in allergic rhinitis: a review. Am Rev Respir Dis. 1991;143:S91-S95.
15. Numata T, Konno A, Yamakoshi T, Hanazawa T, Terada N, Nagata H. Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Ann Otol Rhinol Laryngol. 1999;108:467-473.
16. Fujita M, Yonetomi Y, Shimouchi K, et al. Involvement of cysteinyl leukotrienes in biphasic increase of nasal airway resistance of antigen-induced rhinitis in quinea pigs. Eur J Pharmacol. 1999;369:349-356.
17. Donnelly AL, Glass M, Minkwitz MC, Casale TB. The leukotriene D4-receptor antagonist ICI 204,219 relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med. 1995;151:1734-1739.
18. Pullerits T, Praks L, Skoogh BE, Ani R, Lotvall J. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Resp Crit Care Med. 1999;159:1814-1818.
19. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy. 2001;31:616-624.
20. Reicin A, White R, Weinstein SF, et al. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. Arch Intern Med. 2000;160:2481-2488.
21. Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy. 2001;31:61-68.
22. Wilson AM, Sims EJ, Orr LC, et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2001;87:344-349.
23. Jarvis B, Markham A. Montelukast: a review of its therapeutic potential in persistent asthma. Drugs. 2000;59:891-928.